A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

Study acronym: ENLIGHTEN-2
StatusRecruiting
PhasePhase 3
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial sites reduced: 148 → 143 locations
  2. Trial sites reduced: 157 → 148 locations
    • Eligibility criteria expanded, about 20 words
  3. Study sites: 159 to 157v19
  4. Site details revised at 5 of 159 sitesv18
  5. Site details revised at 23 of 159 sitesv17
Show 15 earlier versionsHide 15 earlier versions
  1. Site details revised at 13 of 159 sitesv16
  2. Site details revised at 11 of 159 sitesv15
  3. Site details revised at 1 of 159 sitesv14
  4. Site details revised at 1 of 159 sitesv13
  5. Site details revised at 2 of 159 sitesv12
  6. Study sites revised (159)v11
  7. Study sites: 158 to 159v10
  8. Site details revised at 2 of 158 sitesv9
  9. Site details revised at 3 of 158 sitesv8
  10. Study sites: 159 to 158v7
  11. Site details revised at 24 of 159 sitesv6
  12. Re-verified, no change to tracked fieldsv5
  13. Site details revised at 2 of 159 sitesv4
  14. Study Status, Referencesv3
  15. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 158 to 159
    • Start date changed from estimate of Jan 2026 to Dec 15, 2025
    v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Eli Lilly
363 trials monitored
See 16 trials at risk
Diabetes
5,101 trials monitored
See 233 trials at risk
Obesity
3,888 trials monitored
See 157 trials at risk
Type 2 Diabetes
2,236 trials monitored
See 113 trials at risk
The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo for body weight reduction in participants with overweight or obesity and type 2 diabetes. Participation in the study will last about 75 weeks.
Trial Details
NCT Number NCT07282600
Lead Sponsor Eli Lilly and Company
Conditions
(from sponsor)		 Overweight, Obesity
Related terms Diabetes Mellitus, Type 2, Obesity, Overweight
Enrollment 1,035 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov